The FDA Just Made It Possible to Build a Drug for One Person

2. Build a natural history baseline. Since you can't run a placebo-controlled trial with one patient, you need detailed data on what happens to untreated patients over time. Think of it as the "before" photo that makes the "after" meaningful.

3. Prove you're hitting the target. Show that your therapy actually engages or edits the thing it's supposed to fix. If you're using CRISPR to correct a mutation, demonstrate that the correction happened.

4. Gather real evidence of benefit. Clinical improvement, a change in disease trajectory, or movement in a well-established biomarker. The FDA still wants to see results, not just a compelling PowerPoint.

5. Meet manufacturing standards. Even if you're making a therapy for one person, it has to be made to full regulatory quality. No garage labs.

For gene-editing therapies specifically, the FDA is adding extra safety requirements. Developers need to run sophisticated sequencing analysis to check for off-target edits (places where the molecular scissors cut in the wrong spot) and screen for chromosomal damage. The agency isn't lowering the bar so much as reshaping it for a different kind of race.

The Backstory: How We Got Here

This framework didn't appear out of nowhere. It's the culmination of a three-year effort that has quietly been reshaping rare disease development behind the scenes.

In May 2023, the Bespoke Gene Therapy Consortium (BGTC) launched after reviewing 62 applications and selecting eight rare diseases for an AAV gene therapy development program. Think of the BGTC as a shared kitchen for chefs who all need the same equipment but are cooking completely different meals.

By February 2024, the consortium released its Regulatory Playbook, essentially a step-by-step guide for assembling the paperwork needed to get these therapies into patients. Later that year, the FDA granted rare pediatric disease and orphan drug designations to all the investigational therapies in the BGTC portfolio.

Then came the proof that speed was possible. In 2025, researchers developed, received FDA clearance for, and delivered a personalized in vivo CRISPR therapy for an infant with CPS1 deficiency (a severe metabolic disorder) in roughly six months. Six months from "let's build this" to "it's in the patient." For context, traditional drug development averages about 10 to 15 years.

That case became the proof of concept the entire field needed. If you can go from design to delivery in half a year, the bottleneck isn't science anymore. It's regulation. And now the FDA is trying to clear that bottleneck.

Who Stands to Win

The companies best positioned to ride this wave already have platforms built for rare and ultra-rare diseases.

Ultragenyx is one of the most obvious beneficiaries. The company has a deep portfolio of genetic disease programs, and its gene therapy DTX401 for glycogen storage disease type Ia already has an FDA action date in late August 2026 with Priority Review status. That timing isn't a coincidence; it shows the rare disease review pipeline is already heating up.

Solid Biosciences (focused on Duchenne muscular dystrophy) and Taysha Gene Therapies (developing a therapy for Rett syndrome) all operate in the exact space this framework is designed to unlock. Ensoma, with its in vivo gene engineering programs, has an IND-cleared program that was expected to enter trials in 2025.

Gene-editing companies like Beam Therapeutics also stand to benefit, since the framework explicitly accommodates editing-based approaches with its new off-target safety guidance.

But the real winners might be companies and consortiums that don't exist yet. By creating a repeatable regulatory path, the FDA is essentially sending a signal to investors: you can build a business around one-patient therapies now. That's a fundamentally different pitch than it was two years ago.

The Elephant in the Room: Who Pays for This?

If the science and regulatory questions are getting answered, the economic question is still wide open. And it's a big one.

Gene therapies already have a pricing problem. Existing treatments can cost from hundreds of thousands to several million dollars per patient. When your therapy is designed for a single person, the entire development cost sits on one set of shoulders. The math gets brutal fast.

Insurers face their own dilemma. They're being asked to pay enormous sums upfront for therapies that might deliver decades of benefit, but the long-term durability data simply doesn't exist yet at the time of launch. It's like buying a car with a lifetime warranty from a company that opened last Tuesday.

Patients with rare diseases also tend to move between insurers over time, which means the payer who funds the treatment may never see the downstream savings. That misalignment kills the economic logic that's supposed to make gene therapy a good deal.

Several creative payment models have been proposed: outcomes-based contracts (pay only if the therapy works), annuity-style payments spread over years, and subscription models where health systems pay a flat fee for access. In practice, though, these models keep running into data gaps, measurement problems, and sheer administrative complexity.

The FDA can build the regulatory on-ramp. But without a parallel revolution in how these therapies get paid for, many bespoke treatments could end up approved on paper and inaccessible in practice.

Why This Matters Beyond Rare Disease

FDA officials have already hinted that the plausible mechanism framework isn't just for N-of-1 therapies. The principles could extend to other rare disease programs where the underlying biology is well characterized, even if the patient population is somewhat larger.

That's the quiet part of this announcement that deserves more attention. If the framework proves workable for ultra-rare diseases, it could become a template for a much broader rethinking of how we approve precision medicines. Every cancer with a known driver mutation, every autoimmune disease with a clear genetic trigger: they all share the same fundamental challenge of small, well-defined patient populations that don't fit neatly into the traditional trial model.

The FDA is still clear that the evidentiary bar remains high. You need robust data, even from small studies, that's strong enough to rule out chance findings. Post-approval monitoring and real-world evidence collection will be expected. This is flexibility with guardrails, not a free pass.

But the signal is unmistakable. The agency is telling the biotech world: if you understand the biology well enough, we'll work with you on the evidence. For patients who've been waiting for treatments that the old system couldn't deliver, that's not just a regulatory update. It's a lifeline.

The drugs of the future might not come in bottles of 10,000. They might come in bottles of one. And now, for the first time, there's a real path to get them there.